24/7 Market News Snapshot 05 August, 2025 – Y-mAbs Therapeutics, Inc. Common Stock (NASDAQ:YMAB)
DENVER, Colo., 05 August, 2025 (www.247marketnews.com) – (NASDAQ:YMAB) are discussed in this article.
Y-mAbs Therapeutics, Inc. has experienced a remarkable surge in its stock price, owing to a significant merger agreement with SERB Pharmaceuticals. Initially opening at $4.25 per share, Y-mAbs’ stock soared to $8.54, representing a staggering increase of 103.82% during a single trading session. This impressive performance, backed by a substantial trading volume of 1.25 million shares, reflects the market’s optimism regarding Y-mAbs’ innovative therapeutic offerings in cancer treatment.
The merger, valued at approximately $412 million, will see SERB Pharmaceuticals acquire Y-mAbs in an all-cash transaction. Under the terms of the agreement, SERB plans to initiate a tender offer to purchase all outstanding shares of Y-mAbs for $8.60 each, providing a remarkable 105% premium over the company’s closing price prior to the announcement. This strategic acquisition is expected to significantly enhance SERB’s product portfolio in the rare oncology sector, particularly by incorporating Y-mAbs’ flagship treatment, DANYELZA® (naxitamab-gqgk).
DANYELZA, noted for being the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma, offers crucial treatment options for pediatric patients battling this aggressive cancer type. The therapy’s ability to be administered in both inpatient and outpatient settings further enhances its accessibility for families dealing with the challenges of cancer treatment.
In a statement, SERB’s CEO, Vanessa Wolfeler, articulated the company’s commitment to expanding DANYELZA’s reach, emphasizing its potential to significantly impact patient outcomes. Meanwhile, Jeremie Urbain, Chairman of SERB, described the acquisition as a pivotal step towards building a global specialty pharmaceutical platform dedicated to rare diseases. The transaction is anticipated to close in the fourth quarter of 2025, subject to customary conditions, reinforcing both organizations’ commitment to innovation and enhanced patient care in oncology.